Lucira Health (NASDAQ:LHDXQ – Get Rating) and Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.
Earnings and Valuation
This table compares Lucira Health and Navidea Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.
Get Lucira Health alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucira Health | $93.06 million | 0.08 | -$64.83 million | ($3.58) | -0.05 |
| Navidea Biopharmaceuticals | $70,000.00 | 135.53 | -$15.18 million | ($0.56) | -0.52 |
Navidea Biopharmaceuticals has lower revenue, but higher earnings than Lucira Health. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Lucira Health, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
57.0% of Lucira Health shares are held by institutional investors. Comparatively, 5.6% of Navidea Biopharmaceuticals shares are held by institutional investors. 30.4% of Lucira Health shares are held by insiders. Comparatively, 45.2% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for Lucira Health and Navidea Biopharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
| Navidea Biopharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Risk & Volatility
Lucira Health has a beta of 3.36, suggesting that its share price is 236% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
Profitability
This table compares Lucira Health and Navidea Biopharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| Navidea Biopharmaceuticals | N/A | N/A | -362.74% |
Summary
Navidea Biopharmaceuticals beats Lucira Health on 6 of the 11 factors compared between the two stocks.
About Lucira Health
(Get Rating)
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
About Navidea Biopharmaceuticals
(Get Rating)
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.